Mark Agulnik, MD

Dr. Pollack characterizes ripretinib as an outstanding fourth-line agent that filled a critical unmet need in post-third-TKI progression settings. Before ripretinib's availability, patients lacked effective treatment options after exhausting the first three lines of therapy.

Dr. Agulnik analyzes the INTRIGUE trial's landmark contributions to GIST management, representing the first head-to-head Phase 3 comparison rather than placebo-controlled study.

Dr. Somaiah outlines the current FDA-approved sequence for advanced KIT-mutant GIST, emphasizing that community oncologists may encounter only handful of patients annually. First-line therapy uses imatinib 400mg daily, escalating to 400mg twice daily for KIT exon 9 mutations based on superior activity data.

Dr. Jason Sicklick from UC San Diego introduces this OncLive Peer Exchange program addressing the evolving post-third-line GIST landscape, joined by sarcoma experts Dr. Mark Agulnik, Dr. Neeta Somaiah, Dr. Michael Heinrich, Dr. Seth Pollack, and Dr. Brian Schulte. The discussion focuses on the first positive Phase 3 second-line trial in over two decades currently under FDA review.

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.

In this episode, experts discuss the landmark SARC 032 study, highlighting the importance of multidisciplinary collaboration.

In this episode, experts discuss the impact of neoadjuvant radiation and immunotherapy on surgical planning in patients with soft tissue sarcomas.

In this episode, experts shed light on the surgical approach to soft tissue sarcomas.

In this episode, experts discuss the potential of radiation therapy to enhance immune response in soft tissue sarcomas.

In this episode, experts discuss the rationale behind the combined treatment in the Stand Up to Cancer SARC 032 trial.

In this episode, experts discuss the latest advancements in the multimodal treatment of undifferentiated pleomorphic sarcoma of the extremities.

Mark Agulnik, MD, discusses the evolving management of heterogeneous disease types in gastrointestinal stromal tumors.

Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.

A panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.

Expert oncologists discuss the recent approval of nirogacestat for the treatment of desmoid tumors and explore its impact on clinical practice and the future treatment landscape.

A panel of oncology experts discuss the impact of nirogacestat on pain symptoms and quality of life indicators for individuals with desmoid tumors, as well as the possible effects on ovarian function.

Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.

Mark Agulnik, MD, examines the mechanism of action of nirogacestat, emphasizing the impact of ϒ-secretase inhibition on NOTCH pathway signaling.

A panel of oncology experts provides insights into the management of desmoid tumors in women, focusing on special considerations for pregnancy and contraception.

Jonathan Trent, MD, PhD, discusses the role of approaches using low-dose and conventional chemotherapy, emphasizing key consideration factors for patient selection.

Mark Agulnik, MD, gives a summary of approaches to systemic therapy in the management of desmoid tumors, highlighting the diminishing role of chemotherapy and the shift towards targeted therapies.

Chandrajit Raut, MD, explores the role of radiotherapy and other locoregional strategies in desmoid tumor management, highlighting the emerging role of cryoablation and HIFU.

Chandrajit Raut, MD, shares expert insights into the evolving role of surgical strategies for desmoid tumor management, emphasizing essential factors in patient selection.

A panel of oncology experts examine the significance of employing active surveillance as a primary strategy in the treatment of desmoid tumors, providing expert insights into this approach.

Mark Agulnik, MD, discusses signs and symptoms commonly presenting with desmoid tumors and their impact on quality of life for patients.

Marilyn Bui, MD, PhD, explores the pathogenesis and diagnosis of desmoid tumors, emphasizing the significance of a multidisciplinary diagnostic approach.

Chandrajit Raut, MD, provides an overview of the landscape surrounding desmoid tumors, highlighting associated epidemiology and common characteristics.